A
Alcista
Alcista · 25%PHAR
$11.40
Precio del escenario
$11.200
+0.557 (+4.97%)Al cierre
Loading chart…
- Máximo
- 11.450
- Apertura
- 11.320
- Precio medio ponderado por volumen
- 11.14
- Volumen
- 25.78K
- Capitalización
- 529.32M
- Mínimo
- 10.760
- Importe
- 287.15K
- EV/EBITDA, TTM
- 39.04
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Análisis de IA of Pharming Group NV (PHAR)
ComprarPharming Group NV is a good buy right now due to its recent positive news regarding FDA approvals and significant revenue growth. The stock is currently priced at $11.20, with a 5-day change of +19.66%, indicating strong momentum. Additionally, the RSI is at 79.978, suggesting that the stock is overbought but also reflects strong buying interest. The forward P/E ratio is high at 212.766, indicating that the stock may be overvalued based on earnings expectations, which is a risk to consider. However, the potential for revenue growth, with an expected increase to approximately $117.6 million in Q3 2026, supports a bullish outlook.
Métricas de valoración
El PER previsto actual de Pharming Group NV (PHAR) es 212.77, frente a su media de 5 años de -38.95.
Escenarios de precio de Alphio AI para PHAR
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
9.510-22NewsfilterPharming Group Announces Q3 2026 Revenue Growth and Guidance Update
- 9.010-14Newsfilter
Pharming Presents Positive Phase II Data for Leniolisib in Primary Immunodeficiencies
7.510-12stocktwitsBiotech Firms Set to Release Key Data This Week
9.009-25NASDAQ.COMFDA Accepts Pharming's Lower Dose Joenja Application
- 9.009-22Newsfilter
Pharming Reports Phase II Clinical Data for Leniolisib in PIDs
Preguntas frecuentes sobre PHAR, respondidas por Alphio AI
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization. It operates in the Healthcare sector.
Pharming Group NV is a good buy right now due to its recent positive news regarding FDA approvals and significant revenue growth. The stock is currently priced at $11.20, with a 5-day change of +19.66%, indicating strong momentum. Additionally, the RSI is at 79.978, suggesting that the stock is overbought but also reflects strong buying interest. The forward P/E ratio is high at 212.766, indicating that the stock may be overvalued based on earnings expectations, which is a risk to consider. However, the potential for revenue growth, with an expected increase to approximately $117.6 million in Q3 2026, supports a bullish outlook.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.